# EB-NK-301

Source: https://onco.cc/drugs/eb-nk-301/  
OnCo record `eb-nk-301` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EB-NK-301 is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials, aimed at TROP2.

## Summary

EB-NK-301 is a CAR-NK cell therapy developed by Beijing Biotech. Its target is TROP2. ClinicalTrials.gov describes the intervention as: Investigational allogeneic CAR-NK cell product targeting TROP2, administered by intravenous infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07589530, plans to enrol 60 participants with primary completion expected 2027-02-14. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: TROP2-CAR NK
- Tags: pipeline; ctgov-ingest
- Modality: CAR-NK cell therapy
- Mechanism: CAR-NK cell therapy directed at TROP2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of EB-NK-301: https://clinicaltrials.gov/search?intr=EB-NK-301

## Connected records

- technologies: [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors](https://onco.cc/trials/nct07589530/)

---
JSON: https://onco.cc/api/v1/entities/eb-nk-301.json